Search
Vemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigational[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF. … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.
Docosanol
go.drugbank.com/drugs/DB00632ApprovedDocosanol is a drug used for topical treatment for recurrent herpes simplex labialis episodes (episodes of cold sores or fever blisters).
Lifileucel
go.drugbank.com/drugs/DB17107ApprovedInvestigational] Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma. … Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341
Acetylcholine
go.drugbank.com/drugs/DB03128ApprovedInvestigationalIt is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications.
Synonyms: O-AcetylcholineBupranolol
go.drugbank.com/drugs/DB08808ExperimentalBupranolol is a non-selective beta blocker with potency similar to [propanolol]. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.
Barbexaclone
go.drugbank.com/drugs/DB09001ExperimentalWith this difference in potency in mind, other pharmacokinetic considerations such as dose titration, daily dosing, and optimal plasma concentration can be considered the same as for the equivalent amount … Barbexaclone, a salt compound of propylhexedrine and phenobarbital, is a potent antiepileptic. By weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital.
Olendalizumab
go.drugbank.com/drugs/DB14834InvestigationalOlendalizumab is under investigation in clinical trial NCT01883544 (Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects).
Motexafin lutetium
go.drugbank.com/drugs/DB05296InvestigationalMotexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin.
Categories: Heterocyclic Compounds with 4 or More RingsSutilain
go.drugbank.com/drugs/DB09379ApprovedWithdrawnIt is able to dissolve the intercellular matrix which helps with desquamation. … [T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368]
Pegademase
go.drugbank.com/drugs/DB00061ApprovedWithdrawnBovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.